Codes and standards
The Code
The GSK Code sets out the commitments GSK and our people make to get ahead together – so we can deliver on our ambition in the right way, bring our culture to life and make GSK an exciting and inspiring place to work.
- The Code - printable version (PDF)
A short PDF which sets out the Code in accessible and plain text - The Code - presentation version (PDF)
A longer PDF which contains images and graphics that bring the Code to life - Policies and standards (PDF)
A summary of our global policies and standards which support the Code
Equal and Inclusive Treatment of Employees
As detailed in our Code of Conduct, we do not tolerate harassment, unwelcome, unreasonable or offensive behaviour or discrimination of any kind. Our Equal and Inclusive Treatment policy is designed to help our employees and complementary workers understand their role in ensuring GSK is a company where all employees are treated equally.
- Equal and Inclusive Treatment of Employees PolicyPDF - 116.1KB
Anti-Bribery and Corruption (ABAC) Programme
The Anti-Bribery and Corruption (ABAC) Programme is part of GSK’s response to the threat and risk of bribery and corruption. The programme includes an ABAC Policy and Standard, which have been designed to help staff and external parties understand bribery and corruption risk, and their responsibilities to actively combat it.
- Anti-Bribery and Corruption PolicyPDF - 330.5KB
Binding Corporate Rules
Our human resources and research and development activities involve the processing of “personal information”, including the transfer of that personal information internationally. We have adopted Binding Corporate Rules (BCRs) to enable us to make international transfers of personal information within our group of companies in compliance with data protection laws of the European Union, in particular the General Data Protection Regulation (Regulation 2016/679) (GDPR).
Find out more about GSK’s Binding Corporate Rules
Third Party Oversight Programme
Our Third Party Oversight Programme helps control risks from third party business engagements with suppliers, distributors and other business partners. We want to work with business partners who share our commitment of high ethical standards and operating in a responsible way.
- Working with Third Parties PDF - 252.4KB
GSK’s public policy statement on Working with Third Parties sets out our expectation that Third Parties will:
- Share our commitment to high ethical standards
- Comply with all applicable laws and regulations and adopt, at a minimum, GSK’s Anti-Bribery & Corruption and Labour Rights Principles
- Where relevant, comply with our standards on quality, patient safety, health and safety and the environment
- Create a culture which supports staff reporting of suspected violations of law, rules and regulations, as well as of unethical conduct, without fear of reprisal or retaliation.
Promotion and Scientific Engagement
- GSK Pharma and Vaccine Code of Practice for Promotion and Scientific EngagementPDF - 214.0KB
- GSK Consumer Healthcare Code of Promotion and Scientific EngagementPDF - 908.2KB
Find out more about us
- Modern Slavery Act statement 2021PDF - 211.0KB
- Modern Slavery Act statement 2020PDF - 191.4KB
- Modern Slavery Act statement 2019PDF - 214.5KB
- Modern Slavery Act statement 2018PDF - 144.6KB
- Modern Slavery Act statement 2017PDF - 208.8KB
- Modern Slavery Act statement 2016PDF - 214.0KB
GlaxoSmithKline plc - Specialised Disclosure Report
- GlaxoSmithKline plc - 2021 Form SD Conflict Minerals DisclosurePDF - 89.9KB
- GlaxoSmithKline plc - 2020 Form SD Conflict Minerals DisclosurePDF - 121.4KB
- GlaxoSmithKline plc - 2019 Form SD Conflict Minerals DisclosurePDF - 16.4KB
- GlaxoSmithKline plc - 2018 Form SD Conflict Minerals DisclosurePDF - 289.5KB
- GlaxoSmithKline plc - 2017 Form SD Conflict Minerals DisclosurePDF - 240.5KB
- GlaxoSmithKline plc - 2016 Form SD Conflict Minerals DisclosurePDF - 1.2MB
- GlaxoSmithKline plc - 2015 Form SD Conflict Minerals DisclosureDOC - 46.5KB
- GlaxoSmithKline plc - 2014 Form SD Conflict Minerals DisclosurePDF - 122.5KB
GlaxoSmithKline plc and GlaxoSmithKline Capital plc Euro Medium Term Note Programme
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document – December 2021PDF - 930.3KB
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document – May 2021PDF - 923.2KB
- GlaxoSmithKline Euro Medium Term Note Programme – Supplementary Prospectus Nov 2020PDF - 60.6KB
- Glaxosmithkline Euro Medium Term Note Programme Prospectus Document 2020PDF - 1.5MB
- GlaxoSmithKline Euro Medium Term Note Programme – Supplementary Prospectus 2020PDF - 73.2KB
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2019PDF - 1.3MB
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2018PDF - 1.1MB
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2017PDF - 506.4KB
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2016PDF - 464.3KB
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2015PDF - 470.4KB
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2014PDF - 462.2KB
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2013PDF - 3.4MB
- GlaxoSmithKline Euro Medium Term Note Programme – Registration DocumentPDF - 86.6KB
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus DocumentPDF - 3.4MB
- GlaxoSmithKline Euro Medium Term Note Programme - Supplementary Prospectus DocumentPDF - 127.0KB
GlaxoSmithKline Capital plc Annual Reports
- 2021 Annual Report GlaxoSmithKline Capital plcPDF - 427.7KB
- 2021 Half Year Results and Interim Management Report GlaxoSmithKline Capital PlcPDF - 244.9KB
- 2020 Annual Report GlaxoSmithKline Capital plcPDF - 429.8KB
- 2020 Half Year Results And Interim Management Report GlaxoSmithKline Capital PlcPDF - 229.4KB
- 2019 Annual Report GlaxoSmithKline Capital plcPDF - 596.3KB
- 2019 Half Year Results and Interim Management Report GlaxoSmithKline Capital plcPDF - 188.0KB
- 2018 Annual Report GlaxoSmithKline Capital plcPDF - 420.1KB
- 2018 Half Year Results and Interim Management Report GlaxoSmithKline Capital plcPDF - 426.7KB
- 2017 Annual Report GlaxoSmithKline Capital plcPDF - 741.4KB
- 2017 Half Year Results and Interim Management Report GlaxoSmithKline Capital plcPDF - 300.9KB
- 2016 Annual Report GlaxoSmithKline Capital plcPDF - 7.3MB
- 2016 Half Year Results and Interim Management Report GlaxoSmithKline Capital plcPDF - 360.4KB
- 2015 Annual Report GlaxoSmithKline Capital plcPDF - 690.5KB
- 2015 Half Year Results and Interim Management Report GlaxoSmithKline Capital plcPDF - 342.2KB
- 2014 Annual Report GlaxoSmithKline Capital plcPDF - 7.9MB
- 2014 Half Year Results and Interim Management Report GlaxoSmithKline Capital plcPDF - 68.2KB
- 2013 Annual Report GlaxoSmithKline Capital plcPDF - 330.7KB
- 2013 Half Year Results and Interim Management Report GlaxoSmithKline Capital plcPDF - 2.1MB
- 2012 Annual Report GlaxoSmithKline Capital plcPDF - 539.8KB
- 2012 Half Year Results and Interim Management Report GlaxoSmithKline Capital plcPDF - 182.0KB
- 2011 Annual Report GlaxoSmithKline Capital plcPDF - 617.4KB
- 2011 Half Year Results and Interim Management Report GlaxoSmithKline Capital plcPDF - 301.3KB
- 2010 Annual Report GlaxoSmithKline Capital plcPDF - 4.9MB
- 2009 Annual Report GlaxoSmithKline Capital plcPDF - 2.9MB
- 2008 Annual Report GlaxoSmithKline Capital plcPDF - 3.5MB